Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 22;16(1):70.
doi: 10.3390/cancers16010070.

Changing Prevalence of AIDS and Non-AIDS-Defining Cancers in an Incident Cohort of People Living with HIV over 28 Years

Anna Maria Cattelan  1 , Maria Mazzitelli  1 , Nicolò Presa  1 , Claudia Cozzolino  2 , Lolita Sasset  1 , Davide Leoni  1 , Beatrice Bragato  1 , Vincenzo Scaglione  1 , Vincenzo Baldo  2 , Saverio Giuseppe Parisi  3
Affiliations

Changing Prevalence of AIDS and Non-AIDS-Defining Cancers in an Incident Cohort of People Living with HIV over 28 Years

Anna Maria Cattelan et al. Cancers (Basel). .

Abstract

Background: The introduction and evolution of antiretrovirals has changed the panorama of comorbidities in people living with HIV (PLWH) by reducing the risk of AIDS-defining cancers (ADC). By contrast, due to ageing and persistent inflammation, the prevalence and incidence of non-AIDS-defining cancers have significantly increased. Therefore, we aimed at describing cancer epidemiology in our cohort over 28 years.

Methods: We retrospectively included all PLWH in our clinic who ever developed cancers, considering features of ADC and NADC, from January 1996 to March 2023. Demographic, clinical characteristics, and survival were analyzed, comparing three observation periods (1996-2003, 2004-2013, and 2014-2023).

Results: A total of 289 PLWH developed 308 cancers over the study period; 77.9% were male, the mean age was 49.6 years (SD 12.2), and 57.4% PLWH developed NADC and 41.5% ADC. Kaposi (21.8%) and non-Hodgkin lymphoma (20.1%) were the most frequent cancers. Age at the time of cancer diagnosis significantly increased over time (41.6 years in the first period vs. 54.4 years in the third period, p < 0.001). In the first period compared with the last, a simultaneous diagnosis of HIV infection and cancer occurred in a higher proportion of persons (42.7 vs. 15.3, p < 0.001). While viro-immunological control at cancer diagnosis significantly improved over time, the proportions of cancer progression/remission remained stable. Overall survival significantly increased, but this trend was not confirmed for ADC.

Conclusions: The probability of survival for ADC did not decrease as significantly as the number of ADC diagnoses over time. By contrast, NADC dramatically increased, in line with epidemiological studies and other literature data. The changing patterns of malignancies from ADC to NADC underline the need for public health interventions and the fostering of screening programs aimed at the prevention and early detection of NADC in PLWH.

Keywords: AIDS-defining cancer; HIV; PLWH; cancer; epidemiology; malignancies; non-AIDS-defining cancer; tumor.

PubMed Disclaimer

Conflict of interest statement

M.M. received a research grant from Gilead, advisory board fees from ViiV Healthcare, and speaker’s honoraria from Gilead and ViiV Healthcare, MSD; A.C., L.S. and D.L. received speaker’s honoraria from Gilead and ViiV Healthcare, MSD; All of the other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Annual raw incidence per 1000 PLWH of ADC and NADC over time.
Figure 2
Figure 2
Differences in time from HIV to cancer diagnosis between ACD and NADC over the three decades. Pairwise comparison p-values marked with * fall below the significance level under Bonferroni correction.
Figure 3
Figure 3
Survival probabilities for all periods (a), all tumor types (b), ADC (c), and NADC (d). Significance values for variations in long- (15-year) and short-term (2-year) survival by group were determined with the log-rank test.
Figure 4
Figure 4
Disease-free survival probabilities for all periods (a), all tumor types (b), ADC (c), and NADC (d). Significance values for variations in long- (15-year) and short-term (2-year) survival by group were determined with the log-rank test.
Figure 4
Figure 4
Disease-free survival probabilities for all periods (a), all tumor types (b), ADC (c), and NADC (d). Significance values for variations in long- (15-year) and short-term (2-year) survival by group were determined with the log-rank test.
See this image and copyright information in PMC

References

    1. Antiretroviral Therapy Cohort Collaboration Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356. doi: 10.1016/S2352-3018(17)30066-8. - DOI - PMC - PubMed
    1. Mazzitelli M., Sasset L., Gardin S., Leoni D., Trunfio M., Scaglione V., Mengato D., Agostini E., Vania E., Putaggio C., et al. Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV. Viruses. 2023;15:1740. doi: 10.3390/v15081740. - DOI - PMC - PubMed
    1. Fabbiani M., Rossetti B., Ciccullo A., Oreni L., Lagi F., Celani L., Colafigli M., De Vito A., Mazzitelli M., Dusina A., et al. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. HIV Med. 2021;22:843–853. doi: 10.1111/hiv.13146. - DOI - PubMed
    1. Mazzitelli M., Milinkovic A., Pereira B., Palmer J., Tong T., Asboe D., Boffito M. Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV. AIDS. 2019;33:2439–2441. doi: 10.1097/QAD.0000000000002403. - DOI - PubMed
    1. Pereira B., Mazzitelli M., Milinkovic A., Casley C., Rubio J., Channa R., Girometti N., Asboe D., Pozniak A., Boffito M. Evaluation of a Clinic Dedicated to People Aging with HIV at Chelsea and Westminster Hospital: Results of a 10-Year Experience. AIDS Res. Hum. Retroviruses. 2022;38:188–197. doi: 10.1089/aid.2021.0083. - DOI - PubMed

LinkOut - more resources